Professor Eriks Rozners and colleagues at Binghamton University in New York, USA, are using innovative nucleic acid chemistry to modify RNA-based technologies such as RNA interference and CRISPR to enhance their utility in molecular biology. These technologies suffer from off-target effects that limit their clinical utility.

By replacing phosphates in the backbone with amides, the team aims to improve the stability, specificity, and uptake of these technologies by cells to make them more suitable for in vivo applications.

Read the original article: doi.org/10.1021/acschembio.2c00769

Read more in Research Outreach